Anzeige
Mehr »
Login
Mittwoch, 28.02.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
Nurexone Biologic: Prof. Levenberg erklärt, wie die ExoTherapy funktioniert!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 850501 | ISIN: US1101221083 | Ticker-Symbol: BRM
Tradegate
27.02.24
21:44 Uhr
46,700 Euro
+0,100
+0,21 %
Branche
Pharma
Aktienmarkt
S&P 100
S&P 500
1-Jahres-Chart
BRISTOL-MYERS SQUIBB COMPANY Chart 1 Jahr
5-Tage-Chart
BRISTOL-MYERS SQUIBB COMPANY 5-Tage-Chart
RealtimeGeldBriefZeit
46,55046,70027.02.
46,45046,70027.02.

Aktuelle News zur BRISTOL-MYERS SQUIBB Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiBristol Myers CEO says India to have largest R&D presence outside US by 202511
DiBristol Myers Squibb acquires RayzeBio for $4.1bn11
MoBristol Myers blueprints $400M Ireland expansion with plans to add sterile drug firepower and hire 35012
MoBristol Myers Squibb completes RayzeBio acquisition13
MoBristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform421PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB). With the completion of the...
► Artikel lesen
FrBristol-Myers Squibb Options Trading: A Deep Dive into Market Sentiment14
FrCHMP provides positive opinion for BMS's Reblozyl6
FrKaruna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout15
FrBristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio71PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc.® ("Mirati"). With the completion...
► Artikel lesen
FrBristol Myers blood disorder therapy endorsed in EU for label expansion7
FrBristol Myers Squibb: Approx. 86% Of RayzeBio Common Stock Validly Tendered As Of Expiration Time382NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) said its tender offer to acquire all of the outstanding shares of RayzeBio, Inc. (RYZB) common stock for a purchase price of $62.50 per share...
► Artikel lesen
FrBristol Myers Squibb Announces Expiration of RayzeBio Tender Offer86PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its previously announced tender offer (the "Offer") to acquire all of the outstanding shares of RayzeBio...
► Artikel lesen
FrBristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)384Approval by European Commission would expand Reblozyl's indication to include first-line treatment of anemia in adults with MDS in Europe In the pivotal Phase 3 COMMANDS study, Reblozyl nearly...
► Artikel lesen
DoA Closer Look at Bristol-Myers Squibb's Options Market Dynamics11
DoImmunocore and BMS partner to investigate first-line treatment for melanoma7
DoBristol Myers Squibb to invest $440m in Dublin facility8
21.02.How Is The Market Feeling About Bristol-Myers Squibb?18
21.02.Novo, Novartis, BMS and J&J win judge's blessing to combine arguments in upcoming IRA hearing28
21.02.Should You Pick Bristol Myers Squibb Stock After A 30% Fall Last Year And Q4 Beat?30
21.02.Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review9
Seite:  Weiter >>
594 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,46